

**RECEIVED
CENTRAL FAX CENTER****JAN 02 2007**

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062

919-862-2200
Fax: 919-862-2260

TELECOPY**PLEASE DELIVER AS SOON AS POSSIBLE****DATE:** January 2, 2007**TO:** Mail Stop Amendment, U.S. Patent & Trademark Office**FROM:** Leslie T. Henry**NO. OF PAGES:**
(Including cover page) 3**OPERATOR:****IF NOT RECEIVED PROPERLY, PLEASE NOTIFY ME IMMEDIATELY AT (919) 862-2277**

USER CODE:	HENRL	FAX NUMBER:	(571) 273-8300
CLIENT/MATTER:	035784/277291		
REQUESTED BY:	Polly Burton, Ext. 2277	VOICE NUMBER:	

ADMIN/2158687v1

RECEIVED
CENTRAL FAX CENTER

JAN 02 2007

Attorney's Docket No. PP017201.0018 (035784/277291)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Shirley <i>et al.</i>	Confirmation No.: 9990
Appl No.:	10/821,333	Group Art Unit: 1647
Filed:	April 9, 2004	Examiner: Jegatheesan Seharaseyon
For:	HSA-FREE FORMULATIONS OF INTERFERON-BETA	

January 2, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

This is in response to the Office Action dated December 4, 2006, in which the Examiner has required Applicants to elect a single disclosed species of buffer for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Further, Applicants are required to include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added.

Applicants hereby elect without traverse "aspartic acid" as the species of buffer for prosecution. Currently, generic claims 1-3 and 5-8 are readable thereon. Applicants expressly reserve the right to file divisional applications or take such other appropriate measures deemed necessary to protect the inventions directed to the non-elected buffer species encompassed by these generic claims.


Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned so that further examination of this application can be expedited.

It is not believed that extensions of time are required. However, in the event that extensions of time are necessary to allow consideration of this paper, such extensions are hereby

Appl No.: 10/821,333
Amdt. Dated January 2, 2007
Reply to Restriction Requirement of December 4, 2006

petitioned under 37 CFR § 1.136(a), and any fee required therefore is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,




Leslie T. Henry
Registration No. 45,714

CUSTOMER NO. 27476
CUSTOMER REPRESENTATIVE'S
NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the US Patent and Trademark Office at Fax No. (571) 273-8300 on the date shown below.


Polly P. Burton

1/2/07
Date

LEGAL02/30197759v1